Natco Pharma to hold 42nd AGM on September 25, 2025 via Video Conferencing
The announcement is about the AGM and other routine corporate actions, which have a neutral impact.
The announcement is about the AGM and other routine corporate actions, so sentiment is neutral.
* Natco Pharma Limited will hold its 42nd Annual General Meeting (AGM) on Thursday, September 25, 2025, at 11:00 A.M. (IST) through Video Conferencing (VC)/Other Audio-Visual Means. * The company will adopt the audited Annual Financial Statements for FY 2024-25. * They will confirm three interim dividends aggregating to ₹6.00 per share paid on equity shares during the Financial Year 2024-25 as dividend for the FY 2024-25. * Re-appointment of Sri Rajeev Nannapaneni (DIN: 00183872) as a Director liable to retire by rotation * Appointment of CS Kiran Kumar Bodla, Proprietor of M/s. BK & Associates as Secretarial Auditors of the Company for a term of 5 years i.e., from the Financial Year 2025-26 to 2029-30 at a remuneration of ₹2,50,000 per annum. * Ratification of remuneration of Cost Auditors of ₹5,00,000 plus taxes as applicable plus out of pocket expenses proposed to be paid to M/s. S.S. Zanwar & Associates to conduct the Cost Audit for the financial year ending March 31, 2026. * The board is authorized to borrow up to ₹1,000 Crore over and above the aggregate of paid-up capital and free reserves and securities premium of the Company at any time. * Increase the Authorized Share Capital of the Company from ₹40,00,00,000 to ₹45,00,00,000 divided into 22,50,00,000 equity shares of ₹2 each. * The remote e-voting will be available from September 22, 2025, 9.00 A.M. (IST) to September 24, 2025, 5.00 P.M. (IST).
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.